Piper Jaffray reiterated an Overweight rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and raised the price target to $168.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change Guidance

Wedbush Raises Price Target on BioMarin Pharma (BMRN) to $139 Following 2Q Results August 5, 2015 6:44 AM BioMarin (BMRN) PT Raised to $173 at Nomura; Increasingly Confident on Drisapersen August 4, 2015 7:24 AM BioMarin Pharma (BMRN) Tops Q2 EPS by 2c, FY Guidance UnchangedAugust 3, 2015 4:04 PM BioMarin Announces Second Quarter 2015 Financial Results and Company UpdateAugust 3, 2015 4:02 PM BioMarin Announces Second Quarter 2015 Financial Results and Company UpdateAugust 3, 2015 4:02 PM Trading Radar for 7/31: Loews (L), Clorox (CLX), Tenet Healthcare (THC), Broadsoft (BSFT) ReportJuly 31, 2015 3:34 PM